NCT01311050Unknown不适用
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 46
- 试验地点
- 1
研究概览
简要总结
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
详细描述
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 14 Years 至 85 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosed Metastatic Colorectal Cancer
排除标准
- •Patients with diagnosis other than Metastatic Colorectal Cancer
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCancer of the GallbladderCancer of the Biliary TractNCT00338988M.D. Anderson Cancer Center44
已完成
不适用
Phase I trial of capecitabine, oxaliplatin and irinotecan combination chemotherapy (XELOXIRI) for advanced gastric cancerAdvanced gastric cancerJPRN-UMIN000022861Kyushu University18
已完成
2 期
Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal CancerColorectal CancerNCT00220116Royal Marsden NHS Foundation Trust172
已完成
1 期
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaPancreatic NeoplasmsBile Duct NeoplasmsNCT00634751University of Wisconsin, Madison48
终止
2 期
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular CancerHepatocellular CancerLiver CancerNCT03026803City of Hope Medical Center4